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DNMT3A mutations are frequent in cytogenetically normal acute myeloid leukemia (cn-AML) patients and
associated with poor survival. The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
DNMT3Amut cn-AML patients remains unclear. In this study, we retrospectively analyzed the prognostic
impact of DNMT3A mutations and explored the role of allo-HSCT in 308 cn-AML patients who received
consolidation of intensive chemotherapy or allo-HSCT in our center from March 2005 to May 2014. In the
whole cohort, 63 patients (20.5%) were identified with DNMT3A exon 23 mutations and R882H was the most
frequent variant. DNMT3Amut patients had shorter overall survival (3-year OS: 31.9% vs. 52.0%, P50.009) and
disease-free survival (3-year DFS: 21.8% vs. 40.1%, P50.004) compared with DNMT3Awt patients. Based on
FLT3/NPM1/CEBPA mutations, 308 cn-AML patients were divided into favorable/intermediate group (n5 262)
and unfavorable group (n5 46). There were no significant differences in 3-year OS and 3-year DFS between
DNMT3Amut and DNMT3Awt patients in both favorable/intermediate and unfavorable groups. Additionally, in
multivariate analysis, DNMT3A mutation remained an independent adverse prognostic factor for the survival.
In the DNMT3Amut cohort, 23 complete remission (CR) patients received allo-HSCT consolidation and 32 CR
patients received chemotherapy consolidation, dramatic differences were observed in 3-year OS (51.7% vs.
28.9%, P50.048) and 3-year DFS (41.6% vs. 14.9%, P50.024) between allo-HSCT group and chemotherapy
group. Collectively, DNMT3A mutation is a poor prognostic factor for cn-AML patients and allo-HSCT could
improve survival of cn-AML patients with DNMT3A mutations.
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 Introduction
Acute myeloid leukemia (AML) is a heterogeneous disorder with regard to morphology and chromosome aberrations detected in the leukemic
cells. Clinical and genetic prognostic markers are now crucial in the evaluation of AML patients and in guiding rational management. Forty to fifty
percent of patients do not have clonal chromosomal aberrations, and all such cases of cytogenetically normal AML (cn-AML) are currently catego-
rized in the intermediate-risk group [1,2]. In recent years, extended molecular analyses have yielded novel molecular markers important for proper
diagnostics and prognostics of AML, including fms-like tyrosine kinase-3 gene (FLT3), nucleophosmin gene (NPM1), and the CCAAT/enhancer
binding protein gene (CEBPA), which provide risk classification for AML at diagnosis in current clinical practice [3–6].
With the development of whole genome sequencing technology, additional recurrently mutated genes in AML were identified. Many of the
mutated genes were involved in epigenetic regulation of transcription, including IDH1/2, TET-2, and DNMT3A [7–11]. DNMT3A, located in chro-
mosomal band 2p23 and, together with DNMT3B and DNMT1, is a member of a DNA methyltransferase (MTase) family, which catalyzes the
addition of methyl groups to cytosine residues of CpG nucleotides [12]. According to published literatures, a range of 11–35% AML patients were
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observed with DNMT3A mutations and the majority of DNMT3A
mutations were missense mutations at residue 882. DNMT3A muta-
tions were also associated with old age, higher white blood cells, nor-
mal cytogenetic, and the presence of NPM1, FLT3-ITD, and IDH1
mutations [13–16]. The function and biological consequences of
DNMT3A mutations have not yet to be fully understood, while a
negative impact on outcomes in cn-AML patients was observed by a
number of studies [17–21]. Currently, only three molecular markers
(NPM1, CEBPA, and FLT3-ITD) have been included in the European
Leukemia Net classification [6], whether DNMT3A will be included
in the future is an interesting question. Moreover, allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) were recommended to
be the first-front therapy for the consolidation of AML patients with
molecular unfavorable factors [6,22,23], however, the clinical benefit
of allo-HSCT consolidation has not been clearly established in cn-
AML patients with DNMT3A mutations.
As the DNMT3A often served as the poor risk factor and R882
mutations was the major mutation, we analyzed DNMT3A R882
mutations together with FLT3, NPM1, and CEBPA to provide risk
classification, and retrospectively analyzed the clinical phenotype,
prognostic impact of DNMT3A mutations and explored treatment
value of allo-HSCT in 308 cn-AML patients who received intensive
consolidation therapy or allo-HSCT.
 Patients and Methods
Patients and treatments. Three hundred and eight adult patients diagnosed with
de novo cn-AML were involved in this study with approval of the ethics committee
of our hospital from March 2005 to May 2014. All cn-AML patients received
induction chemotherapy consisted of standard first-line treatment of an IA (Idaru-
bicin and cytarabine)-like regimen comprised of Idarubicin 8–12 mg/m2 (Days 1–3)
and cytarabine 100 mg/m2 (Days 1–7), and after achieving first complete remission
(CR) patients received consolidation of either at least four cycles of intermediate/
high-dose cytarabine (1–2 g/m2 over 3 hr for 3 days)-based combination chemo-
therapy (n5 94) or allo-HSCT treatment (n5 214).
HSCT patients received a conditioning regimen consisting of cytarabine (2 g/
m2/day for 2 days), busulfan (3.2 mg/kg/day for 3 days, intravenously), and
cyclophosphamide (1.8 g/m2/day for 2 days). Patients with high risk of central
nervous system leukemia received a similar regimen, but with total body irradia-
tion (8 Gy, lung shielding at 6.5 Gy, on Day -6) substituted for busulfan and
cytarabine started on Day -8. The patients who are considered poor candidates
for myeloablative conditioning due to advanced age or other concurrent medical
conditions were conditioned with fludarabine 30 mg/m2 (Days -6 to -2), cytara-
bine 2 g/day (on Days -5 and -2), rabbit antithymocyte globulin (ATG;
Genzyme, Cambridge, MA) 1.5 mg/kg/day (on Days -5 to -2), and cyclophos-
phamide 30 mg/kg/day (on Days -3 to -2). Graft-versus-host disease (GVHD)
prophylaxis consisted of continuous cyclosporine infusion at 3 mg/kg/day start-
ing on Day -1 until patients could switch to oral intake (PO), with a target
blood concentration ranging from 200 to 300 ng/ml, and short term methotrex-
ate given on Days 11, 13, 16, and 111 at doses of 15, 10, 10, and 10 mg/m2,
respectively.
Cytogenetic and mutation analyses. The bone marrow (BM) samples of de novo
AML patients were processed using standard 24-hr unstimulated cultures. A con-
ventional R-banding assay was used for karyotypic analysis. When possible, at least
20 metaphases per sample were analyzed. Genomic DNA was extracted from BM-
derived mononuclear cells using the PurelinkTM Genomic DNA mini kit (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s instructions. A variety of acute
leukemia-related gene mutations were evaluated, including FLT3-ITD, FLT3-TKD,
NPM1, CEBPA, and DNMT3A. In this study, only DNMT3A exon 23 mutations
were analyzed. The gene mutations were detected by PCR amplification of the
entire or a portion of the coding region followed by direct bidirectional DNA
sequencing in cn-AML patients.
Statistical analyses. A student’s t-test was used to compare the age, WBC (white
blood cells) count, hemoglobin, platelet count, and BM blasts at diagnosis in the
different groups. The v2 test was used to analyze the interrelation for different gene
mutations. Overall survival (OS) was measured as the time from the date of disease
diagnosis to the date of death or last follow-up. Disease-free survival (DFS) was
defined as the time from disease diagnosis to CR, first relapse, or death. A Kaplan–
Meier analysis was used to calculate the distribution of OS and DFS. All quoted P
values were from two-tailed tests and confidence intervals refer to 95% boundaries.
All calculations were performed using the SPSS software package (version 19.0;
IBM).
 Results
Clinical characteristics of the 308 cn-AML patients
Three hundred and eight adult de novo cn-AML patients were
involved in this study from March 2005 to May 2014. The median
age was 40 years (range: 16–68 years), and there are 144 males and
164 females. Based on French–American–British (FAB) criteria, there
were 5 (1.6%) patients classified as M0, 55 (17.9%) as M1, 74 (24.0%)
as M2, 53 (17.2%) as M4, 75 (24.4%) as M5, 16 (5.2%) as M6, 3
(1.0%) as M7, and 27 (8.8%) that were unclassified AML patients.
The median blast in BM was 56.12%, and the median white cell
counts was 25.22 (0.5–355.9)*109/L. Based on FLT3-ITD/NPM1/
CEBPA risk classification, the total 308 cn-AML patients could be
divided into unfavorable risk group (n5 46, harboring FLT3-ITD
mutation) and favorable/intermediate risk group (n5 262, other
mutations). Two hundred and twenty-six cn-AML patients achieved
CR with one cycle of induction therapy and 271 cn-AML patients
achieved CR with two cycles of induction therapy. In these CR
patients, 188 patients received allo-HSCT and 83 patients received
consolidation of intermediate/high-dose cytarabine chemotherapy.
Additionally, 37 patients who were no remission with induction ther-
apy received salvage therapy of allo-HSCT (n5 26) or Decitabine
combined intermediate dose cytarabine chemotherapy (n5 11).
Frequencies of DNMT3A mutations and clinical
features in cn-AML patients
As shown in Table I, 63 (20.4%) cn-AML patients were identified
with DNMT3A exon 23 mutations in a total cohort of 308 cn-AML
patients, and the distribution of mutations was as follows: R882H
(n5 36), R882C (n5 12), R882P (N5 6), R882H&C (n5 2), and
others (n5 7). The median age of DNMT3A mutated patients was elder
than that of the control group (P< 0.001), while there were no signifi-
cant differences in sex, white cell counts, and blast percentage in periph-
eral blood (PB) and BM between patients with and without DNMT3A
mutations. However, regarding to FAB distributions, more M5 patients
(38.1%) were observed in DNMT3A mutated group compared with the
controls (20.8%) group (P< 0.001). FLT3-ITD and NPM1 mutations
were also more often observed in DNMT3A mutated group (P< 0.001).
Clinical outcome of cn-AML patients with DNMT3A
mutations
The median follow-up time for cn-AML patients was 30 months
(range: 6–98 months). Compared with DNMT3Awt patients,
DNMT3Amut patients had a lower 3-year OS (31.9% vs. 52.0%,
P5 0.009) and 3-year DFS (21.8% vs. 40.1%, P 50.004) (Supporting
Information), suggesting DNMT3A mutations might serve as a poor
prognostic factor. The survival of all 308 cn-AML patients were fur-
ther analyzed according to FLT3-ITD/NPM1/CEBPA risk classifica-
tion, and the validity of FLT3-ITD/NPM1/CEBPA risk classification
was verified by the median OS time (favorable: not reached; interme-
diate: 41 months; unfavorable: 12 months, P< 0.001) and DFS time
(favorable: 36 months; intermediate: 15 months; unfavorable: 7
months, P5 0.003). Notably, there was no significant difference in
OS (3-years OS: 39.5% vs. 53.5%, P5 0.210) and DFS (3-years DFS:
24.8% vs. 41.2%, P5 0.091) between DNMT3Amut and DNMT3Awt
patients in favorable/intermediate group, and similar results were
observed in OS and DFS between DNMT3Amut and DNMT3Awt
patients in unfavorable group (3-year OS: 21.6% vs. 29.3%, P5 0.582;
3-year DFS: 17.4% vs. 23.9%, P5 0.508). (Fig. 1)
Multivariate analyses for outcomes in cn-AML patients
In the total 308 DNMT3A mutated patients, 214 patients received
allo-HSCT consolidation while 94 patients received at least four cycles
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of intermediate dose cytarabine-based combination chemotherapy.
We then performed multivariate analyses including age (<45 years
vs. >45 years), treatment (allo-HSCT vs. chemotherapy), white blood
cell counts, hemoglobin counts, platelet counts, ECOG score, FLT3-
ITD/NPM1/CEBPA risk classification, and DNMT3A mutations on
the end point OS and DFS in the total 308 cn-AML patients. The
results revealed that age, treatment, FLT3-ITD/NPM1/CEBPA risk
classification, and DNMT3A mutations were significantly and inde-
pendently associated with a worse OS and DFS, while high white
blood cell counts were associated with a worse OS and DFS and low
ECOG score was associated with a better DFS in univariate analysis
(Table II).
allo-HSCT could improve survival of cn-AML with
DNMT3A mutations
Fifty-five (55/63, 87.3%) DNMT3A mutated patients finally
achieved CR with induction therapy. In these patients, 23 patients
received allo-HSCT consolidation while 32 patients received at least
four cycles of high-dose cytarabine-based combination chemotherapy.
No significant differences were observed in age, sex, FAB distribution,
BM blast, and other mutations in these two groups (Supporting
Information). Interestingly, the 3-year OS (51.7% vs. 28.9%,
P5 0.048) and 3-year DFS (41.6% vs. 14.9%, P5 0.024) were dramat-
ically improved in allo-HSCT group. When we limited this compari-
son to the favorable/intermediate risk group only, significant
differences were also observed in both 3-year OS (56.0% vs. 34.8%;
P5 0.036) and 3-year DFS (41.9% vs. 16.7%; P5 0.047) between
these two groups (Fig. 2). Meanwhile, based on DNMT3A mutations,
the total HSCT cohort (n5 214) were further divided into
DNMT3Awt group (n5 189) and DNMT3Amut group (n5 25) and
the patients characteristic were listed in Supporting Information. No
differences were observed in age, donor type, condition regimen,
GVHD prophylaxis between two groups, and the 3-year OS (46.7%
vs. 57.2%, P5 0.731) and 3-year DFS (35.2% vs. 38.5%, P5 0.871)
were similar in these two groups. In addition, with respect to favor-
able/intermediate risk group, there were also no differences in 3-year
OS (52.7% vs. 59.1%; P5 0.599) and 3-year DFS (39.4% vs. 40.7%;
P5 0.569) between DNMT3Awt and DNMT3Amut groups (Supporting
Information). These results might indicate that allo-HSCT could
reverse the poor outcome of cn-AML with DNMT3A mutations.
TABLE I. Clinical Characteristics of the 308 cn-AML Patients
Total
(n5 308)
DNMT3Amut
(n5 63)
DNMT3Awt
(n5245) P
Age (years)
Median (range) 40 (16–68) 44 (16–68) 39 (18–65) <0.001
Gender 0.420
Male 144 21 33.3% 123 50.2%
Female 164 42 66.7% 122 49.8%
ECOG 0.536
0 53 11 17.5% 42 17.1%
1 164 30 47.6% 134 54.7%
2 91 22 34.9% 69 28.2%
FAB <0.001
M0 5 2 3.2% 3 1.2%
M1 55 0 0.0% 55 22.5%
M2 74 15 23.8% 59 24.1%
M4 53 14 22.2% 39 15.9%
M5 75 24 38.1% 51 20.8%
M6 16 0 0.0% 16 6.5%
M7 3 0 0.0% 3 1.2%
Unknown 27 8 12.7% 19 7.8%
Blast in PB (%)
Median 53.70 45.19 55.49 0.200
Blast in BM (%)
Median 56.12 57.47 55.78 0.768
White cells (109/L)
Median (range) 25.22 (0.5–355.9) 29.49 (0.67–204) 24.15 (0.5–355.9) 0.323
Hb (g/L)
Median (range) 85 (29–157) 76.5 (36–157) 86 (29–157) 0.307
Platelets (109/L)
Median (range) 45 (6–985) 56.5 (8–443) 38 (6–985) 0.132
FLT3-ITD
mut 46 24 38.1% 22 9.0% <0.001
wt 262 39 61.9% 223 91.0%
NPM1
mut 69 30 47.6% 39 15.9% <0.001
wt 239 33 52.4% 206 84.1%
CEBPA
mut 24 4 6.3% 20 8.2% 0.795
wt 284 59 93.7% 225 91.8%
FLT3-ITD/NPM1 27 19 70.4% 8 29.6% <0.001
FLT3-ITD/CEBPA 4 3 75.0% 1 25.0% 0.028
NPM1/CEBPA/FLT3-ITD
Favorable/intermediate 262 39 61.9% 223 91.0% <0.001
Unfavorable 46 24 38.1% 22 9.0%
CR 271 55 87.3% 216 88.2% 0.851
Abbreviation: PB: Peripheral blood; BM: Bone Marrow; Hb: Hemoglobin; CR: Complete Remission.
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Figure 1. Kaplan–Meier survival curves for cn-AML patients with different FLT3-ITD/CEBPA/NPM1 risk classification. (A) OS of cn-AML patients in favorable,
intermediate, and unfavorable groups. (B) DFS of cn-AML patients in favorable, intermediate, and unfavorable groups. (C) OS of cn-AML patients with and
without DNMT3A mutations in favorable/intermediate group. (D) DFS of cn-AML patients with and without DNMT3A mutations in favorable/intermediate group.
(E) OS of cn-AML patients with and without DNMT3A mutations in unfavorable group. (F). DFS of cn-AML patients with and without DNMT3A mutations in
unfavorable group.
TABLE II. Results of Univariate and Multivariate Analysis for OS and DFS in cn-AML
OS DFS
Univariate Multivariate Univariate Multivariate
P HR 95%CI P P HR 95%CI P
Age (<45 years vs. >45 years) 0.004 2.07 1.19–3.61 0.011 0.002 1.75 1.17–2.63 0.007
White cells (<median vs. >median) 0.041 1.41 0.85–2.35 0.179 0.044 1.12 0.83–1.65 0.237
DNMT3A (mut vs. wt) 0.011 1.50 1.08–3.07 0.047 0.005 1.72 1.14–3.44 0.044
FLT3-ITD/NPM1/CEBPA (favorable/intermediate
vs. unfavorable)
0.000 2.74 1.09–7.57 0.014 0.002 2.14 1.13–4.07 0.020
Treatment (allo-HSCT vs. chemotherapy) 0.002 1.56 1.08–3.23 0.046 0.029 1.98 1.11–3.93 0.048
ECOG score (<2 vs. >52) 0.068 1.38 0.96–2.02 0.919 0.025 1.09 0.69–1.71 0.712
Hb (<median vs. >median) 0.523 0.92 0.55–1.53 0.744 0.801 0.92 0.62–1.36 0.870
Platelet (<median vs. >median) 0.809 1.06 0.63–1.78 0.829 0.566 0.99 0.66–1.47 0.952
Abbreviation: OS: Overall survival; DFS: Disease-free survival; HR: Hazard ratio; CI: Confidence interval; allo-HSCT: allogeneic hematopoietic stem cell trans-
plantation; Hb: Hemoglobin.
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 Discussions
Somatic DNA methyl transferase 3A (DNMT3A) mutations are
recurrent molecular aberrations in AML and associated with poor
survival. In a cohort of 308 cn-AML patients, our data showed that
DNMT3A mutations were among the most common mutations in cn-
AML, occurring in 20.4% of patients, with more frequency in older
patients, and were significantly associated with NPM1 and FLT3-ITD
mutations. Notably, Renneville et al. reported that in a 123 adult cn-
AML cohort, 36 (29%) patients had DNMT3A mutations and 30
(83%) mutations affected the animo-acid residue R882 [16]. In this
study, we found that there were no differences with respect to sex,
BM blast percentage or WBC count between DNMT3A wt and
DNMT3Amut cases, which was inconsistent with other reports
[15,16]. We speculated that the inconsistency might due to only
DNMT3A exon23 mutated cases were included in this study. In addi-
tion, a series of studies have suggested that the presence of DNMT3A
mutations in AML was associated with poor clinical outcomes. Thol
et al. showed that DNMT3A mutations remained an independent
negative prognostic marker for OS [15]. Marcucci et al. find adverse
impact on OS in the subgroup analysis based on the age stratification
[24]. In this report, we found that DNMT3A mutated cn-AML
patients had shorter DFS and OS, and DNMT3A mutation remained
an independent adverse prognostic factor for clinical outcome. Our
study provided key insight into the prognostic value of DNMT3A
mutations in cn-AML patients. However, it should be noted that
DNMT3A non-R882 mutations were not included in this study.
According to previous reports, non-R882 mutations accounted for
minority of DNMT3A mutations (<40%), and the reason for the high
prevalence of R882 was unclear [14]. It was reported that DNMT3A
R882 and non-R882 mutations had different clinical implications in
patients younger and older than 60 years of age [24]. Interestingly,
Gaidzik et al. reported that in younger adults with AML DNMT3A
R882 mutation was an unfavorable marker while non-R882 mutation
was a favorable marker [25].
As DNMT3A mutations often confer a poor prognosis in cn-AML,
we further investigated whether or not allo-HSCT could reverse the
poor survival of cn-AML with DNMT3A mutation. In this study, we
found that allo-HSCT significantly improved the OS of cn-AML with
DNMT3A mutation, and DNMT3Amut patients received allo-HSCT
had the similar survival with the DNMT3Awt cn-AML patients. Dose
intensified chemotherapy was reported to improve the outcome of
the DNMT3A mutated cases [26]. However, several studies also
showed that DNMT3A mutations did not have any effect on RFS and
OS of patients who have undergone allo-HSCT [17,26]. Our study
might provide direct evidence for the benefit of allo-HSCT in
DNMT3Amut cn-AML patients. In a recent publication, Bejar et al.
used massively parallel sequencing to investigate 40 recurrent muta-
tions and explored these mutations predict outcome after allo-HSCT
in 87 patients with MDS, 16 patients with DNMT3A mutations (18%)
were identified and DNMT3A mutations were associated with
decreased OS [27].
Integrated mutational profiling can improve initial risk stratifica-
tion of AML patients, and the mutated genes with robust data sup-
porting its independent prognostic value in AML patients could enter
the integrated panel. To date, only NPM1, CEBPA, and FLT3-ITD
mutations have entered clinical practice and affect risk stratification
and treatment decision-making in cn-AML. Considering high occur-
rence and prognostic significance, it is likely that DNMT3A mutations
belong to this category in cn-AML. In this study, we found that
DNMT3A mutations were associated with FLT3-ITD and NPM1
Figure 2. Kaplan–Meier survival curves for cn-AML patients with DNMT3A mutations followed allo-HSCT or chemotherapy. (A) OS of cn-AML patients with
DNMT3A mutations in favorable/intermediate group. (B) DFS of cn-AML patients with DNMT3A mutations in favorable/intermediate group. (C) OS of cn-AML
patients with DNMT3A mutations. (D) DFS of cn-AML patients with DNMT3A mutations.
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mutations in cn-AML patients. Based on FLT-ITD/NPM1/CEBPA
gene mutations, the cn-AML patients were divided into two groups
(favorable/intermediate and unfavorable). We compared the clinical
outcomes in different groups and found that no significant differences
were observed in OS and DFS between DNMT3Amut and DNMT3Awt
patients in both unfavorable/intermediate and unfavorable groups. It
was reported that in a multivariate analysis included NPM1/FLT3-
ITD/CEBPA low- versus high-risk mutational status and DNMT3A as
covariate in cn-AML patients, high WBC count at presentation,
NPM1/FLT3-ITD/CEBPA high-risk genotypes and DNMT3A muta-
tions were significantly and independently associated with a worse
EFS and OS [16]. In addition, Ribeiro et al. also found that DNMT3A
mutations were independent factor for worse OS in their multivariate
analysis including FLT3/NPM1 mutational status [17]. In this study,
211 patients (211/308, 68.5%) in this cohort were assigned to inter-
mediate group and 46 patients (46/308, 15.0%) were assigned to
unfavorable group. Most patients (214/308, 69.5%) patients of total
cohort had received allo-HSCT treatment, which might improve sur-
vival of all cn-AML patients. Moreover, other gene mutations were
likely to dictate both prognosis and potential therapeutic responsive-
ness in cn-AML. Pooling more clinical data in future and well-
designed clinical trial will be helpful to learn more about prognostic
value of DNMT3A in combination other recurrent gene mutations in
cn-AML patients.
DNMT3A is a key gene for the epigenetic regulation of human
cells as the encoded enzyme is known to be a major player in the de
novo DNA methylation at CpG sites. Much remains to be learned on
the precise leukemogenic effect of the epigenetic changes caused by
DNMT3A mutations. Recently, de novo AML patients with concur-
rent DNMT3A, FLT3, and NPM1 mutations had been suggested to
represent a unique AML subset, and DNMT3A had a significant
dominant effect on clinical outcomes of these subset patients [28]. It
was reported that cells bearing mutations in DNMT3A but not NPM1
were present at diagnosis in AML patients and persist at remission
and relapse. The results indicated that DNMT3Amut arises early in
AML evolution, probably in HSCs, leading to a clonally expanded
pool of preleukaemic HSCs from which AML evolves [29]. Interest-
ingly, it was also reported that DNMT3A mutations presented in
remission samples from 14 patients up to 8 years after initial AML
diagnosis, and the presence of DNMT3A mutations in leukaemic
blasts, but also at lower allele frequencies in T and B-cells from the
same patients [30]. These results might provide a new insight into
the role of DNMT3A in leukemogenic effect and management of
AML therapy.
In conclusion, our results suggested that DNMT3A mutation was a
poor prognostic factor for cn-AML patients and allo-HSCT could
improve survival of cn-AML patients with DNMT3A mutations.
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